Upcoming Events
HSCRB Department Seminar
Yenching Library Auditorium
Friday, Sept. 19
12:00-1:00 PM

HSCI Technology Series: Lineage Differentiation/Disease-in-a-Dish
Sherman Fairchild 201
Tuesday, Sept. 23
12:00-1:00 PM

HSCI Technology Series: Imaging
HMS, TMEC 109
Wednesday, Oct. 15
12:00-1:00 PM

Boston Single Cell Network Meeting
MGH Darwin Room
Tuesday, Oct. 21
4:30-6:00 PM
Announcements
Reminder: Quantity discounts and reduced rates for internal customers (Harvard and HSCI faculty) at the iPS Core.

Visit the core website for the complete list of iPS Core derivation and genome editing services and costs.
Recognitions
Biomedical engineer Sangeeta Bhatia, MD, PhD, wins the Lemelson-MIT Prize.
Job Postings
HSCI in the New York Times
David Scadden, MD, and Kevin Eggan, PhD, comment on the trials of stem cell therapy.
As researchers in Japan embark on the first clinical trial evaluating iPSCs for age-related macular degeneration, The New York Times surveys the stem cell therapy landscape. "Progress comes in fits and starts," Scadden said. "when we look back 20 years from now, I think medicine and human health will be transformed by [stem cell research]."
Non-toxic strategy to treat leukemia
Harvard/MIT team finds that killing cancer cells by disrupting their metabolism doesn't harm normal cells
A study comparing how blood stem cells and leukemia cells consume nutrients found that cancer cells are far less tolerant to shifts in their energy supply than their normal counterparts. The results suggest that there could be ways to target leukemia metabolism so that cancer cells die but other cell types are undisturbed. The work, led by David Scadden, MD, was published in Cell. Read the full story.
Review: Stem cell-based therapies for cancer
From Khalid Shah, PhD, and Daniel Stuckey, PhD, of MGH
This review "considers the current status of stem cell-based treatments for cancer and provides a rationale for translating the most promising preclinical studies into the clinic." Download the paper from Nature Reviews: Cancer.